As at Apr 2, 2025, the UTHR stock has a PE ratio of 11.81. This is based on the current EPS of $26.44 and the stock price of $312.26 per share. A decrease of 9% has been seen in the P/E ratio compared to the average of 13.0 of the last 4 quarters.
The mean historical PE ratio of UNITED THERAPEUTICS over the last ten years is 12.95. The current 11.81 PE ratio is 9% below the historical average. Over the past ten years, UTHR's PE ratio was at its highest in the Jun 2015 quarter at 47.14, with a price of $173.95 and an EPS of $3.69. The Jun 2016 quarter recorded the bottom point at 4.74, with a price of $105.92 and an EPS of $22.35.
Maximum annual increase: 254.1% in 2013
Maximum annual decrease: -76.49% in 2010
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 13.34 | 27.66% | $352.84 | $26.44 |
2023 | 10.45 | -39.94% | $219.89 | $21.04 |
2022 | 17.4 | -14.62% | $278.09 | $15.98 |
2021 | 20.38 | 56.41% | $216.08 | $10.6 |
2020 | 13.03 | N/A | $151.79 | $11.65 |
2019 | N/A | N/A | $88.08 | -$2.39 |
2018 | 8.04 | -48.36% | $108.9 | $13.54 |
2017 | 15.57 | 76.93% | $147.95 | $9.5 |
2016 | 8.8 | -20.36% | $143.43 | $16.29 |
2015 | 11.05 | -39.75% | $156.61 | $14.17 |
2014 | 18.34 | -43.4% | $129.49 | $7.06 |
2013 | 32.4 | 254.1% | $113.08 | $3.49 |
2012 | 9.15 | -26.21% | $53.42 | $5.84 |
2011 | 12.4 | -62.93% | $47.25 | $3.81 |
2010 | 33.45 | -76.49% | $63.22 | $1.89 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 13.34 | -9.5% | $352.84 | $26.44 |
Sep 2024 | 14.74 | 6.81% | $358.35 | $24.31 |
Jun 2024 | 13.8 | 34.37% | $318.55 | $23.09 |
Mar 2024 | 10.27 | -1.72% | $229.72 | $22.36 |
Dec 2023 | 10.45 | -10.84% | $219.89 | $21.04 |
Sep 2023 | 11.72 | 0% | $225.87 | $19.28 |
Jun 2023 | 11.72 | -17% | $220.75 | $18.83 |
Mar 2023 | 14.12 | -18.85% | $223.96 | $15.86 |
Dec 2022 | 17.4 | 29.75% | $278.09 | $15.98 |
Sep 2022 | 13.41 | -20.51% | $209.38 | $15.61 |
Jun 2022 | 16.87 | 43.45% | $235.64 | $13.97 |
Mar 2022 | 11.76 | -42.3% | $179.41 | $15.26 |
Dec 2021 | 20.38 | 13.92% | $216.08 | $10.6 |
Sep 2021 | 17.89 | 5.3% | $184.58 | $10.32 |
Jun 2021 | 16.99 | -7.16% | $179.41 | $10.56 |
Currently, UTHR's PE ratio is below the 3, 5 and 10-year averages.
UTHR's PE ratio is lower than its peer stocks LLY and PFE.
Stock name | PE ratio | Market cap |
---|---|---|
UTHR UNITED THERAPEUTICS Corp | 11.81 | $14.02B |
PFE Pfizer Inc | 17.39 | $139.98B |
CAH Cardinal Health Inc | 25.73 | $33.5B |
LLY ELI LILLY & Co | 69.58 | $775.81B |
GILD Gilead Sciences Inc | 294.45 | $139.34B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $17.34B |
BAX Baxter International Inc | N/A | $17.22B |
CYTK Cytokinetics Inc | N/A | $4.77B |
As of Apr 2, 2025, UTHR stock has a price to earnings ratio of 11.81.
The 3-year average PE ratio for UTHR stock is 13.44.
The 5-year average PE ratio for UTHR stock is 14.11.
Over the last ten years, the quarterly PE ratio reached a historic high of 47.14 in the Jun 2015 quarter.
UTHR's current price to earnings ratio is 9% below its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Apr 2, 2025), UNITED THERAPEUTICS's stock price is $312.26. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $26.44. Therefore, UNITED THERAPEUTICS's P/E ratio for today is 11.81. PE RATIO(11.81) = STOCK PRICE($312.26) / TTM EPS($26.44)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.